$UTHR
UNITED THERAPEUTICS Corp Stock $uthr

$uthr Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000108255422000004 Filed on February 24, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$415.2M	$1.686B	$384.9M
YoY Change	7.87%	13.63%	23.72%
Cost Of Revenue	$34.60M	$122.5M	$34.80M
YoY Change	-0.57%	13.32%	20.83%
Gross Profit	$380.6M	$1.563B	$350.1M
YoY Change	8.71%	13.66%	24.02%
Gross Profit Margin	91.67%	92.73%	90.96%
Selling, General & Admin	$126.9M	$464.5M	$158.7M
YoY Change	-20.04%	9.58%	50.86%
% of Gross Profit	33.34%	29.72%	45.33%
Research & Development	$82.90M	$540.1M	$126.1M
YoY Change	-34.26%	50.99%	11.0%
% of Gross Profit	21.78%	34.56%	36.02%
Depreciation & Amortization	$12.60M	$49.90M	$13.10M
YoY Change	-3.82%	0.0%	4.8%
% of Gross Profit	3.31%	3.19%	3.74%
Operating Expenses	$209.8M	$540.1M	$284.8M
YoY Change	-26.33%	50.99%	30.16%
Operating Profit	$170.8M	$555.9M	$65.30M
YoY Change	161.56%	-6.35%	2.83%
Interest Expense	-$26.90M	$18.60M	-$53.40M
YoY Change	-49.63%	-20.85%	-1670.59%
% of Operating Profit	-15.75%	3.35%	-81.78%
Other Income/Expense, Net	-$2.400M	$38.00M	$102.5M
YoY Change	-102.34%	-16.11%	7221.43%
Pretax Income	$140.5M	$593.9M	$114.4M
YoY Change	22.81%	-7.04%	67.5%
Income Tax	$28.30M	$118.1M	$15.60M
% Of Pretax Income	20.14%	19.89%	13.64%
Net Earnings	$112.2M	$475.8M	$98.80M
YoY Change	13.56%	-7.58%	87.83%
Net Earnings / Revenue	27.02%	28.23%	25.67%
Basic Earnings Per Share		$10.60
Diluted Earnings Per Share	$2.342M	$10.06	$2.186M
COMMON SHARES
Basic Shares Outstanding	45.04M shares	44.90M shares	44.44M shares
Diluted Shares Outstanding		47.30M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.931B	$1.931B	$1.835B
YoY Change	5.22%	5.22%	23.49%
Cash & Equivalents	$894.8M	$894.8M	$738.7M
Short-Term Investments	$1.036B	$1.036B	$1.096B
Other Short-Term Assets	$100.4M	$100.4M	$88.30M
YoY Change	13.7%	13.7%	-34.01%
Inventory	$93.80M	$93.80M	$86.50M
Prepaid Expenses
Receivables	$198.7M	$198.7M	$157.4M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.324B	$2.324B	$2.167B
YoY Change	7.22%	7.22%	16.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$780.9M	$780.9M	$731.6M
YoY Change	6.74%	6.74%	-0.93%
Goodwill	$28.00M		$28.00M
YoY Change	0.0%		0.0%
Intangibles
YoY Change
Long-Term Investments	$1.650B	$1.650B	$1.150B
YoY Change	43.52%	43.52%	49.79%
Other Assets	$108.2M	$370.1M	$169.9M
YoY Change	-36.32%	-9.4%	9.9%
Total Long-Term Assets	$2.846B	$2.846B	$2.448B
YoY Change	16.25%	16.25%	19.47%
TOTAL ASSETS
Total Short-Term Assets	$2.324B	$2.324B	$2.167B
Total Long-Term Assets	$2.846B	$2.846B	$2.448B
Total Assets	$5.169B	$5.169B	$4.615B
YoY Change	12.01%	12.01%	17.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.800M	$3.800M	$4.100M
YoY Change	-7.32%	-7.32%	-58.59%
Accrued Expenses	$170.8M	$170.8M	$182.9M
YoY Change	-6.62%	-6.62%	32.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$305.4M	$305.4M	$323.3M
YoY Change	-5.54%	-5.54%	-30.17%
LONG-TERM LIABILITIES
Long-Term Debt	$800.0M	$800.0M	$800.0M
YoY Change	0.0%	0.0%	33.33%
Other Long-Term Liabilities	$104.8M	$104.8M	$96.50M
YoY Change	8.6%	8.6%	37.86%
Total Long-Term Liabilities	$104.8M	$904.8M	$96.50M
YoY Change	8.6%	0.93%	37.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$305.4M	$305.4M	$323.3M
Total Long-Term Liabilities	$104.8M	$904.8M	$96.50M
Total Liabilities	$1.210B	$1.210B	$1.220B
YoY Change	-0.79%	-0.79%	7.66%
SHAREHOLDERS EQUITY
Retained Earnings	$4.315B		$3.839B
YoY Change	12.39%		15.46%
Common Stock	$2.246B		$2.149B
YoY Change	4.5%		4.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.959B	$3.959B	$3.395B
YoY Change
Total Liabilities & Shareholders Equity	$5.169B	$5.169B	$4.615B
YoY Change	12.01%	12.01%	17.93%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$112.2M	$475.8M	$98.80M
YoY Change	13.56%	-7.58%	87.83%
Depreciation, Depletion And Amortization	$12.60M	$49.90M	$13.10M
YoY Change	-3.82%	0.0%	4.8%
Cash From Operating Activities	$174.6M	$598.2M	$126.2M
YoY Change	38.35%	-20.84%	23.12%
INVESTING ACTIVITIES
Capital Expenditures	-$70.60M	$120.8M	-$12.30M
YoY Change	473.98%	103.71%	-50.2%
Acquisitions		$0.00
YoY Change
Other Investing Activities	-$125.2M	-$366.1M	-$51.50M
YoY Change	143.11%	-46.1%	-156.66%
Cash From Investing Activities	-$195.8M	-$486.9M	-$63.80M
YoY Change	206.9%	-34.07%	-196.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.500M	$44.80M	6.100M
YoY Change	22.95%	-365.09%	-104.07%
NET CHANGE
Cash From Operating Activities	174.6M	$598.2M	126.2M
Cash From Investing Activities	-195.8M	-$486.9M	-63.80M
Cash From Financing Activities	7.500M	$44.80M	6.100M
Net Change In Cash	-13.70M	$156.1M	68.50M
YoY Change	-120.0%	51933.33%	266.31%
FREE CASH FLOW
Cash From Operating Activities	$174.6M	$598.2M	$126.2M
Capital Expenditures	-$70.60M	$120.8M	-$12.30M
Free Cash Flow	$245.2M	$477.4M	$138.5M
YoY Change	77.04%	-31.45%	8.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001082554
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	uthr	Defined Benefit Plan Vesting Period DefinedBenefitPlanVestingPeriod	P6M
CY2021	uthr	Defined Contribution Plan Annual Increments DefinedContributionPlanAnnualIncrements	0.33
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2019	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	0-26301
CY2021	dei	Entity Registrant Name EntityRegistrantName	United Therapeutics Corporation
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-1984749
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1040 Spring Street,
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Silver Spring,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20910
CY2021	dei	City Area Code CityAreaCode	(301)
CY2021	dei	Local Phone Number LocalPhoneNumber	608-9292
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2021	dei	Trading Symbol TradingSymbol	UTHR
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	7912099590	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45132102	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	894800000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	738700000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1035900000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1096300000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	198700000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	157400000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	93800000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	86500000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	100400000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	88300000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2323600000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2167200000	USD
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1649900000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1149600000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	44600000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	158100000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	780900000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	731600000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	261900000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	238600000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	108200000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	169900000	USD
CY2021Q4	us-gaap	Assets Assets	5169100000	USD
CY2020Q4	us-gaap	Assets Assets	4615000000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	174600000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	187000000.0	USD
CY2021Q4	uthr	Share Tracking Award Plans ShareTrackingAwardPlans	102400000	USD
CY2020Q4	uthr	Share Tracking Award Plans ShareTrackingAwardPlans	96800000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	28400000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	39500000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	305400000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	323300000	USD
CY2021Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	800000000.0	USD
CY2020Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	800000000.0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	104800000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	96500000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	1210200000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1219800000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	245000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	245000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71727021	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71126314	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45107805	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44507098	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	700000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	700000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2245400000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2148700000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23000000.0	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14200000	USD
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	26619216	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	26619216	shares
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2579200000	USD
CY2020Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2579200000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4315000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3839200000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3958900000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3395200000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5169100000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4615000000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1685500000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1483300000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1448800000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1685500000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1483300000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1448800000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	122500000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	108100000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	117600000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	540100000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	357700000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1182600000	USD
CY2021	uthr	Selling General And Administrative Expense And Adjustments SellingGeneralAndAdministrativeExpenseAndAdjustments	467000000.0	USD
CY2020	uthr	Selling General And Administrative Expense And Adjustments SellingGeneralAndAdministrativeExpenseAndAdjustments	423900000	USD
CY2019	uthr	Selling General And Administrative Expense And Adjustments SellingGeneralAndAdministrativeExpenseAndAdjustments	336200000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	1129600000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	889700000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1636400000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	555900000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	593600000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-187600000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	16700000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	28600000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	44200000	USD
CY2021	us-gaap	Interest Expense InterestExpense	18600000	USD
CY2020	us-gaap	Interest Expense InterestExpense	23500000	USD
CY2019	us-gaap	Interest Expense InterestExpense	44200000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42200000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	49300000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22600000	USD
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	2300000	USD
CY2020	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	9100000	USD
CY2019	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	38000000.0	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45300000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22600000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	593900000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	638900000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-165000000.0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118100000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-60500000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	475800000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.60
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.65
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.06
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.54
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44900000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44200000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43800000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47300000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44600000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43800000	shares
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	5600000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4700000	USD
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-8000000.0	USD
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-10600000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax	600000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax	1300000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax	-1700000	USD
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-6200000	USD
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	6700000	USD
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	12300000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15000000.0	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6700000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000000.0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8800000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6300000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	467000000.0	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	514800000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110800000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2788600000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000000.0	USD
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	12300000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4100000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2100000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9900000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	85100000	USD
CY2019	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	10800000	USD
CY2019	uthr	Deconsolidation Of Variable Interest Entity DeconsolidationOfVariableInterestEntity	-100000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2780400000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6700000	USD
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	6700000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3700000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33800000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66000000.0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3395200000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	475800000	USD
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-15000000.0	USD
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-6200000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5600000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	10800000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000000.0	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	51900000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3958900000	USD
CY2019	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	10800000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	475800000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	49900000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	49900000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45900000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	138500000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	163800000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	45400000	USD
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	2300000	USD
CY2020	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	9100000	USD
CY2019	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	USD
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	19200000	USD
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	5400000	USD
CY2019	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	17200000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	113400000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	92600000	USD
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	3400000	USD
CY2019	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	2600000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-65900000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	47000000.0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	29700000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	41300000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6000000.0	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-24400000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7500000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10300000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-12900000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-12500000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	38600000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-16300000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	112900000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-20200000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	199300000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	598200000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	755700000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-206600000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	120800000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59300000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	83700000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2400000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	39700000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1895300000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2308800000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1271500000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1370100000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1523400000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	799200000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	47600000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	76500000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	180900000	USD
CY2021	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	111500000	USD
CY2020	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	27300000	USD
CY2019	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	20500000	USD
CY2021	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2019	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	8000000.0	USD
CY2021	uthr	Decrease In Cash Due To Deconsolidation Of Variable Interest Entity DecreaseInCashDueToDeconsolidationOfVariableInterestEntity	0	USD
CY2020	uthr	Decrease In Cash Due To Deconsolidation Of Variable Interest Entity DecreaseInCashDueToDeconsolidationOfVariableInterestEntity	0	USD
CY2019	uthr	Decrease In Cash Due To Deconsolidation Of Variable Interest Entity DecreaseInCashDueToDeconsolidationOfVariableInterestEntity	12500000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-486900000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-738500000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-335400000	USD
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	800000000.0	USD
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	50000000.0	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	200000000.0	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1700000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	700000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000000.0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33800000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9900000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	5600000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4700000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4100000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10800000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3700000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2100000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44800000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-16900000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	611200000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	156100000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	300000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	69200000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738700000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738400000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	669200000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	894800000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738700000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738400000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	16200000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	20700000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	41000000.0	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	153300000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	92800000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	120200000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3700000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3500000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	54500000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business Description<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. On September 30, 2021, we converted to a Delaware public benefit corporation, with the express public benefit purpose</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have approval from the U.S. Food and Drug Administration (</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FDA</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to market the following therapies: Tyvaso</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Solution (</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Tyvaso</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Remodulin</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Injection (</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Orenitram</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Extended-Release Tablets (</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Orenitram</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Unituxin</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dinutuximab) Injection (</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Unituxin</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and Adcirca</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (tadalafil) Tablets (</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Adcirca</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). We also derive revenues outside the United States from sales of Tyvaso, Remodulin, and Unituxin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As used in these notes to our consolidated financial statements, unless the context otherwise requires, the terms “</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">we</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, “</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">us</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, “</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">our</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.</span></div>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'DIN Offc',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in accordance with GAAP requires our management to make estimates and assumptions that affect reported amounts of assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates on assumptions regarding historical experience, currently available information, and anticipated developments that we believe are reasonable and appropriate. However, because the use of estimates involves an inherent degree of uncertainty, actual results could differ from those estimates. Estimates are used for, but not limited to, revenue recognition, share-based compensation, determining the fair value of assets acquired and liabilities assumed in business combinations, marketable investments, fair value measurements (including those related to contingent consideration), inventory reserves, investments in privately-held companies, income taxes, goodwill and other intangible assets, and obligations related to our Supplemental Executive Retirement Plan.</span></div>
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17600000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	18400000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	31900000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	29500000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	44300000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	38600000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	93800000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	86500000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	28000000.0	USD
CY2021Q4	us-gaap	Goodwill Goodwill	28000000.0	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	28000000.0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	28000000.0	USD
CY2021Q4	uthr	Goodwill And Other Intangibles Assets Gross GoodwillAndOtherIntangiblesAssetsGross	50200000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5600000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	44600000	USD
CY2020Q4	uthr	Goodwill And Other Intangibles Assets Gross GoodwillAndOtherIntangiblesAssetsGross	163600000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5500000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	158100000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1123300000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1040900000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	342400000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	309300000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	780900000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	731600000	USD
CY2021	us-gaap	Depreciation Depreciation	49800000	USD
CY2020	us-gaap	Depreciation Depreciation	49700000	USD
CY2019	us-gaap	Depreciation Depreciation	45700000	USD
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	19200000	USD
CY2021	uthr	Number Of Disclosed Commercially Approved Products NumberOfDisclosedCommerciallyApprovedProducts	5	product
CY2021	uthr	Increase In Net Product Sales IncreaseInNetProductSales	2100000	USD
CY2020	uthr	Increase In Net Product Sales IncreaseInNetProductSales	500000	USD
CY2019	uthr	Decrease In Net Sales Revenue DecreaseInNetSalesRevenue	2300000	USD
CY2021	uthr	Rebates And Chargebacks Maximum Eligible Payment Period RebatesAndChargebacksMaximumEligiblePaymentPeriod	P6M
CY2021Q4	uthr	Accrued Rebates And Chargebacks AccruedRebatesAndChargebacks	67800000	USD
CY2020Q4	uthr	Accrued Rebates And Chargebacks AccruedRebatesAndChargebacks	65300000	USD
CY2021	uthr	Revenue Deduction Rebates And Chargebacks RevenueDeductionRebatesAndChargebacks	218600000	USD
CY2020	uthr	Revenue Deduction Rebates And Chargebacks RevenueDeductionRebatesAndChargebacks	195900000	USD
CY2019	uthr	Revenue Deduction Rebates And Chargebacks RevenueDeductionRebatesAndChargebacks	178700000	USD
CY2021	uthr	Prompt Pay Discount Maximum Eligible Payment Period PromptPayDiscountMaximumEligiblePaymentPeriod	P30D
CY2021	uthr	Expiration Period For Right To Return Product ExpirationPeriodForRightToReturnProduct	P12M
CY2021	uthr	Decrease In Allowance For Product Returns DecreaseInAllowanceForProductReturns	3900000	USD
CY2020	uthr	Allowance For Product Returns AllowanceForProductReturns	0	USD
CY2019	uthr	Decrease In Allowance For Product Returns DecreaseInAllowanceForProductReturns	6200000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	2661400000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2600000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9300000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2654700000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2654700000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	2233600000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000000.0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2246500000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2246500000	USD
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	2300000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	1003800000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	1004800000	USD
CY2021Q4	uthr	Available For Sale Securities Debt Maturities Rolling Year One Through Three Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughThreeAmortizedCostBasis	1657600000	USD
CY2021Q4	uthr	Available For Sale Securities Debt Maturities Rolling Year One Through Year Three Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughYearThreeFairValue	1649900000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	2661400000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2654700000	USD
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	70400000	USD
CY2020Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	78400000	USD
CY2021	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	111500000	USD
CY2020	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	27300000	USD
CY2019	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	20500000	USD
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	92600000	USD
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	3400000	USD
CY2019	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	2600000	USD
CY2020	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	9100000	USD
CY2019	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	USD
CY2021	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3800000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4100000	USD
CY2021Q4	uthr	Accrued Sales Related Royalties Rebates And Fees Current AccruedSalesRelatedRoyaltiesRebatesAndFeesCurrent	85300000	USD
CY2020Q4	uthr	Accrued Sales Related Royalties Rebates And Fees Current AccruedSalesRelatedRoyaltiesRebatesAndFeesCurrent	84500000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	53600000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	47900000	USD
CY2021Q4	uthr	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	19000000.0	USD
CY2020Q4	uthr	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	27800000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12900000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22700000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	170800000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	182900000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	174600000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	187000000.0	USD
CY2021Q4	uthr	Number Of Equity Incentive Plans NumberOfEquityIncentivePlans	2	plan
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	138500000	USD
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	191508	shares
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000000.0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	163800000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45400000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1000000.0	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1000000.0	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	700000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	405536	shares
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	466731	shares
CY2021	uthr	Number Of Months Of Salary Taken As Gross Base For Receipt Of Monthly Payments NumberOfMonthsOfSalaryTakenAsGrossBaseForReceiptOfMonthlyPayments	P36M
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33800000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9900000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	26600000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	22900000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11500000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	5300000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	5400000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	2600000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	475800000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44900000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44200000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43800000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2400000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	400000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47300000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44600000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43800000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.60
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.65
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.06
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.54
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6600000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7200000	shares
CY2021	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-9400000	USD
CY2021	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-600000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8800000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	112300000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	114600000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	63100000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	24600000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20000000.0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9400000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	136900000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	134600000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	72500000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-10100000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1600000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-120100000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-8700000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-12100000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-12900000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18800000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10500000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-133000000.0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118100000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-60500000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	124700000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	134200000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34700000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-18700000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3100000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5700000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	14600000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7000000.0	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3100000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	11800000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	11500000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	6300000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	11500000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	24000000.0	USD
CY2021	uthr	Defined Benefit Plan Eligibility Age DefinedBenefitPlanEligibilityAge	P60Y
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	21300000	USD
CY2021	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	2800000	USD
CY2020	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	2200000	USD
CY2019	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	3300000	USD
CY2021	uthr	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	-1000000.0	USD
CY2020	uthr	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	4800000	USD
CY2019	uthr	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	-300000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1000000.0	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-4100000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-1600000	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5100000	USD
CY2021	uthr	Effective Income Tax Rate Reconciliation Deconsolidation Of Vie EffectiveIncomeTaxRateReconciliationDeconsolidationOfVie	0	USD
CY2020	uthr	Effective Income Tax Rate Reconciliation Deconsolidation Of Vie EffectiveIncomeTaxRateReconciliationDeconsolidationOfVie	0	USD
CY2019	uthr	Effective Income Tax Rate Reconciliation Deconsolidation Of Vie EffectiveIncomeTaxRateReconciliationDeconsolidationOfVie	1900000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118100000	USD
CY2021Q4	uthr	Deferred Tax Assets Supplemental Executive Retirement Plan DeferredTaxAssetsSupplementalExecutiveRetirementPlan	10900000	USD
CY2020Q4	uthr	Deferred Tax Assets Supplemental Executive Retirement Plan DeferredTaxAssetsSupplementalExecutiveRetirementPlan	10900000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-60500000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.20
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.19
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.37
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	186100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	176000000.0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	73400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	73100000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	18300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	18800000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9700000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	1400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	7400000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5000000.0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5600000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	303400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	301500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	291900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	266000000.0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	28200000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	26100000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1800000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1300000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	30000000.0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	27400000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	261900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	238600000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3600000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4500000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4500000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	500000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	100000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	500000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3800000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	700000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	700000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	1500000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3600000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4500000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	400000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	-100000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	300000	USD
CY2021Q4	uthr	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	3900000	USD
CY2020Q4	uthr	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	4900000	USD
CY2019Q4	uthr	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	0	USD
CY2021	uthr	Defined Benefit Plan Eligibility Age DefinedBenefitPlanEligibilityAge	P60Y
CY2020Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	68600000	USD
CY2019Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	56100000	USD
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	3400000	USD
CY2020	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2800000	USD
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	900000	USD
CY2020	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	1300000	USD
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	0	USD
CY2020	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	0	USD
CY2021	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	5800000	USD
CY2020	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-8400000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	67100000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	68600000	USD
CY2021Q4	us-gaap	Defined Benefit Pension Plan Liabilities Current DefinedBenefitPensionPlanLiabilitiesCurrent	18200000	USD
CY2020Q4	us-gaap	Defined Benefit Pension Plan Liabilities Current DefinedBenefitPensionPlanLiabilitiesCurrent	19100000	USD
CY2021Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	48900000	USD
CY2020Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	49500000	USD
CY2021	uthr	Period For Retire Eligible Participants For Benefits Payments PeriodForRetireEligibleParticipantsForBenefitsPayments	P1Y
CY2021Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0205
CY2020Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0149
CY2021Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0400
CY2020Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0400
CY2021Q4	uthr	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Lump Sum Distribution Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationLumpSumDistributionRate	0.0275
CY2020Q4	uthr	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Lump Sum Distribution Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationLumpSumDistributionRate	0.0225
CY2021	uthr	Defined Benefit Plan Benefit Obligation Increase Decrease For Discount Rate DefinedBenefitPlanBenefitObligationIncreaseDecreaseForDiscountRate	1300000	USD
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Period Increase Decrease DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease	4000000	USD
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	3400000	USD
CY2020	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2800000	USD
CY2019	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2200000	USD
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	900000	USD
CY2020	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	1300000	USD
CY2019	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	1400000	USD
CY2021	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	700000	USD
CY2020	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	1300000	USD
CY2019	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	1500000	USD
CY2021	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	0	USD
CY2020	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	0	USD
CY2019	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	2200000	USD
CY2021	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	0	USD
CY2020	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	0	USD
CY2019	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	1900000	USD
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	5000000.0	USD
CY2020	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	5400000	USD
CY2019	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	1000000.0	USD
CY2021	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	5800000	USD
CY2020	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	-8400000	USD
CY2019	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	-12900000	USD
CY2021	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	-700000	USD
CY2020	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	-1300000	USD
CY2019	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	-1500000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Before Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Before Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Before Tax OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax	-1900000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	-6500000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	7100000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	13300000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	-300000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	400000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	1000000.0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-6200000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	6700000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	12300000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	2000000.0	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-3800000	USD
CY2019Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	4500000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	1300000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	2000000.0	USD
CY2019Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	3300000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	-700000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	5800000	USD
CY2019Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	-1200000	USD
CY2021Q4	uthr	Defined Benefit Plan Accumulated Other Comprehensive Income Tax Amount DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeTaxAmount	-1200000	USD
CY2020Q4	uthr	Defined Benefit Plan Accumulated Other Comprehensive Income Tax Amount DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeTaxAmount	-900000	USD
CY2019Q4	uthr	Defined Benefit Plan Accumulated Other Comprehensive Income Tax Amount DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeTaxAmount	-1200000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	500000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	6700000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	0	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	59100000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	58700000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	18200000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	6300000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	16500000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	6800000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	0	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter	38900000	USD
CY2021Q4	uthr	Defined Benefit Plan Expected Future Benefit Payments DefinedBenefitPlanExpectedFutureBenefitPayments	86700000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.40
CY2021	uthr	Defined Contribution Plan Vesting Of Matching Contribution Service Period DefinedContributionPlanVestingOfMatchingContributionServicePeriod	P3Y
CY2021	uthr	Defined Contribution Plan Annual Increments Vesting Period DefinedContributionPlanAnnualIncrementsVestingPeriod	P3Y
CY2021	uthr	Defined Contribution Plan Vesting Of Matching Contribution Service Period DefinedContributionPlanVestingOfMatchingContributionServicePeriod	P3Y
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3100000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2400000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1800000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7200000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18900000	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	3600000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	3500000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	4900000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1685500000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	122500000	USD
CY2021	us-gaap	Gross Profit GrossProfit	1563000000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1483300000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	108100000	USD
CY2020	us-gaap	Gross Profit GrossProfit	1375200000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1448800000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	117600000	USD
CY2019	us-gaap	Gross Profit GrossProfit	1331200000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1685500000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1483300000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1448800000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	780900000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	731600000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	738500000	USD
CY2019Q1	uthr	Upfront Payment UpfrontPayment	800000000	USD

Files In Submission

Name	View Source	Status
0001082554-22-000004-index-headers.html	Edgar Link	pending
0001082554-22-000004-index.html	Edgar Link	pending
0001082554-22-000004.txt	Edgar Link	pending
0001082554-22-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uthr-20211231.htm	Edgar Link	pending
uthr-20211231.xsd	Edgar Link	pending
uthr-20211231_cal.xml	Edgar Link	unprocessable
uthr-20211231_def.xml	Edgar Link	unprocessable
uthr-20211231_g1.jpg	Edgar Link	pending
uthr-20211231_htm.xml	Edgar Link	completed
uthr-20211231_lab.xml	Edgar Link	unprocessable
uthr-20211231_pre.xml	Edgar Link	unprocessable
uthrexh10571231202110k.htm	Edgar Link	pending
uthrexh211231202110k.htm	Edgar Link	pending
uthrexh23112312021.htm	Edgar Link	pending
uthrexh3111231202110k.htm	Edgar Link	pending
uthrexh3121231202110k.htm	Edgar Link	pending
uthrexh3211231202110k.htm	Edgar Link	pending
uthrexh3221231202110k.htm	Edgar Link	pending
uthrexh421231202110k.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UTHR
UNITED THERAPEUTICS Corp Stock $uthr

2021 Q4 Form 10-K Financial Statement

#000108255422000004 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UTHR UNITED THERAPEUTICS Corp Stock $uthr

2021 Q4 Form 10-K Financial Statement

#000108255422000004 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UTHR
UNITED THERAPEUTICS Corp Stock $uthr